Pharmaceutical opinion : **Interaction between potent inducers and anti-HCV**

Patient : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ DOB \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Telephone : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

After analyzing your patient's file, I noticed a problem with his medication.

**Glecaprevir / Pibrentasvir (Maviret)**   **and**

**Anti-TBs :**

* Rifampicin (Rifadin)
* Rifabutin (Mycobutin)

**Interaction mechanism :** Rifampicin is a potent CYP 3A4 and P-gp inducer. Rifabutin is a potent P-gp inducer and a moderate CYP 3A4 inducer. Glecaprevir/Pibrentasvir (Maviret) is a substrate of P-gp. This induction can therefore significantly decrease the plasma concentration of the above-mentioned anti-HCVs, thus leading to a loss of clinical efficacy.

***Glecaprevir / Pibrentasvir (Maviret) and anti-TBs***

Additional information:

Glecaprevir/Pibrentasvir 300/120 mg QD + Rifampicin 600 mg QD : ↓88% and ↓87% of glecaprevir and pibrentasvir AUC, respectively. According to the product monograph, concomitant use of Glecaprevir/ Pibrentasvir (Maviret) with potent P-gp/CYP 3A4 inducers such as rifampicin or rifabutin is contraindicated.

Possible therapeutic options (Anti-TBs):

* Treat mycobacterium before treatment for hepatitis C.
* Re-evaluate the mycobacterial treatment and replace the anti-TB drug with an alternative that does not cause interactions with the anti-HCVs.

Dosage : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ REN : \_\_\_\_\_\_\_

* Other :\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ REN : \_\_\_\_\_\_\_

**Follow-up :** Efficacy of anti-HCV and effectiveness and safety of the chosen alternative drug.

Do not hesitate to contact us for additional information.
In collaboration,

Pharmacist : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Telephone : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_​ Fax : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

As a prescription, date and sign:

Date : \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Signature and licence : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_